

# Gynecology Oncology (GynOnc) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart

## METASTATIC/ UNRESECTABLE

## MUTATIONS

### UCI 22-78

KSQ-4279 +/- Olaparib or Carboplatin  
Targeting deleterious mutation (germline  
or somatic)

Coord: Jiana Ejbara

Accrual: 0/5

### UCI 23-186

Long-term safety and efficacy of  
Pembrolizumab

Coord: Jiana Ejbara

Accrual: 0/8

## PLATINUM-RESISTANT RECURRENCE

<4L

>3L

### GOG-3076

Platinum Doublet + Bevacizumab +/-OlviVec  
Coord: Jiana Ejbara  
Accrual: 2/5

## PLATINUM-SENSITIVE RECURRENCE

FRa + and >1L

### GOG-3078

Mirvetuximab Soravtansine  
Coord: Jiana Ejbara  
Accrual: 0/5

## OVARIAN CANCER

### **UCI 21-190**

Assessing the Predictive Capability of Circulating  
Tumor DNA as a Screening Tool for Ovarian  
Cancer

ctDNA

Coord: Jiana Ejbara

Accrual: 2/36

### **UCI 22-40**

VIRGO2

Coord: Jiana Ejbara

Accrual: